Publications

To evaluate the impact of active surveillance on prostate cancer outcomes requires many participants and a long follow-up time. With ten years of enrollment and more than 1,300 participants, PASS has now accrued enough data to begin publishing results. See below for a list of our peer-reviewed scientific publications.

Estimating and Comparing Cancer Progression Risks Under Varying Surveillance Protocols.
Lange JM, Gulati R, Leonardson AS, Lin DW, Newcomb LF, Trock BJ, Carter HB, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Etzioni R. Ann. Appl. Stat., 2018 Sep 11. 12(3):1773-1795.

Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS).
Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW. J Urol. 2018 Aug 1. pii: S0022-5347(18)43635-X.
doi: 10.1016/j.juro.2018.07.065. [Epub ahead of print] PMID: 30076904.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.
Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, … Zsofia Kote-Jarai Nat Commun. 2018 Jun 11;9(1):2256.
doi: 10.1038/s41467-018-04109-8. PMID: 29892050.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, … Eeles RA. Nat Genet. 2018 Jul;50(7):928-936.
doi: 10.1038/s41588-018-0142-8. Epub 2018 Jun 11. PMID: 29892016.

Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
Kearns JT, Faino AV, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y, Lin DW. Eur Urol. 2018 May;73(5):706-712.
doi: 10.1016/j.eururo.2018.01.016. Epub 2018 Feb 9. PMID: 29433973.

Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y. Eur Urol. 2018 Aug;74(2):211-217.
doi: 10.1016/j.eururo.2018.01.017. Epub 2018 Feb 9. PMID: 29433975.

Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.
Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R. Ann Intern Med. 2018 Jan 2; 168(1): 1-9.
doi: 10.7326/M17-0548. Epub 2017 Nov 28. PMID: 29181514

Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
Lin DW, Newcomb LF, Brown MD, Sjoberg DD, Dong Y, Brooks JD, Carroll PR, Cooperberg M, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y, for the Canary Prostate Active Surveillance Study Investigators. Eur Urol. 2017 Sep; 72(3): 448-454.
doi: 10.1016/j.eururo.2016.11.017. Epub 2016 Nov 23. PMID: 27889277

Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. 
Macleod LC, Ellis WJ, Newcomb LF, Zheng Y, Brooks JD, Carroll PR, Gleave ME, Lance RS, Nelson PS, Thompson IM Jr, Wagner AA, Wei JT, Lin DW.  J Urol. 2017 Apr; 197(4): 1026-1033.
doi: 10.1016/j.juro.2016.10.090. Epub 2016 Nov 1. PMID: 27810448

A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment. 
Liss MA, Schenk JM, Faino AV, Newcomb LF, Boyer H, Brooks JD, Carroll PR, Dash A, Fabrizio MD, Gleave ME, Nelson PS, Neuhouser ML, Wei JT, Zheng Y, Wright JL, Lin DW, Thompson IM.  Prostate Cancer Prostatic Dis. 2016 Dec; 19(4): 390-394.
doi: 10.1038/pcan.2016.28. Epub 2016 Jul 19. PMID: 27431498

Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. 
Newcomb LF, Thompson IM Jr, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW; Canary PASS Investigators. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.  J Urol. 2016 Feb; 195(2): 313-20.
doi: 10.1016/j.juro.2015.08.087. Epub 2015 Aug 29. PMID: 26327354

Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator.
Ankerst DP, Xia J, Thompson IM Jr, Hoefler J, Newcomb LF, Brooks JD, Carroll PR, Ellis WJ, Gleave ME, Lance RS, Nelson PS, Wagner AA, Wei JT, Etzioni R, Lin DW.  Eur Urol. 2015 Dec; 68(6): 1083-8.
doi: 10.1016/j.eururo.2015.03.023. Epub 2015 Mar 25. PMID: 25819722

Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.
Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, Wei JT, Nelson PS; Canary Prostate Active Surveillance Study Investigators.    Clin Cancer Res. 2013 May 1; 19(9): 2442-50.
doi: 10.1158/1078-0432.CCR-12-3283. Epub 2013 Mar 20. PMID: 23515404

Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. 
Newcomb LF, Brooks JD, Carroll PR, Feng Z, Gleave ME, Nelson PS, Thompson IM, Lin DW. Urology. 2010 Feb; 75(2): 407-13.
doi: 10.1016/j.urology.2009.05.050. Epub 2009 Sep 16. PMID: 19758683